Form 4 for VCEL Vericel Corp
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0001140361-26-006973 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-26 | 2026-02-24 | VCEL | Hopper Jonathan Mark | Chief Medical Off | M - OptEx | $0.00 | +6,500 | 71.4K | +10% | $0 |
| DM | 2026-02-26 | 2026-02-24 | VCEL | Hopper Jonathan Mark | Chief Medical Off | F - Tax | $38.14 | -1,971 | 73.2K | -3% | -$75.2K |
| DM | 2026-02-26 | 2026-02-24 | VCEL | Hopper Jonathan Mark | Chief Medical Off | M - OptEx | — | +6,500 | 6,000 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-24 | M | A | 3,150 | $0.00 | 74,527 | D | — | — | (F4) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. (F3) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 2 | Common | Common Stock | 2026-02-24 | F | D | 636 | $38.25 | 75,556 | D | — | — | (F3) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 3 | Common | Common Stock | 2026-02-24 | F | D | 1,335 | $38.09 | 73,192 | D | — | — | (F5) These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. (F3) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 4 | Common | Common Stock | 2026-02-24 | M | A | 1,500 | — | 74,692 | D | — | — | (F1) The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. (F6) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. (F3) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 5 | Common | Common Stock | 2026-02-24 | M | A | 1,500 | $0.00 | 76,192 | D | — | — | (F7) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. (F3) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 6 | Common | Common Stock | 2026-02-24 | M | A | 350 | — | 71,377 | D | — | — | (F1) The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. (F2) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. (F3) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| 7 | Derivative | Restricted Stock Unit | 2026-02-24 | M | A | 1,500 | — | 7,500 | D | — · — to — | 1,500 Common Stock | (F6) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. (F8) Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. (F9) No expiration date for this type of award. |
| 8 | Derivative | Restricted Stock Unit | 2026-02-24 | M | A | 3,150 | — | 10,500 | D | — · — to — | 3,150 Common Stock | (F10) The Fair Market Value of the vested derivative securities is $38.09 per share. (F8) Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. (F4) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. (F9) No expiration date for this type of award. |
| 9 | Derivative | Restricted Stock Unit | 2026-02-24 | M | A | 350 | — | 13,650 | D | — · — to — | 350 Common Stock | (F2) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. (F8) Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. (F9) No expiration date for this type of award. |
| 10 | Derivative | Restricted Stock Unit | 2026-02-24 | M | A | 1,500 | — | 6,000 | D | — · — to — | 1,500 Common Stock | (F11) The Fair Market Value of the vested derivative securities is $38.25 per share. (F8) Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. (F7) The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. (F9) No expiration date for this type of award. |